Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Building a balanced search formula for pharmacovigilance and literature monitoring
Posted on March 21st, 2017 by Xuanyan Xu in Pharmacovigilance
Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, the large volume of events to be reviewed and negative media coverage, have compelled regulatory authorities to implement new and more strict pharmacovigilance legislation emphasizing patient safety and public health.
A recent report from the European Commission has revealed that since the introduction of new rules on monitoring the safety of medicines, it has been successful at engaging patients and allowing them to report directly to the regulators. New legislation continues to focus on the relevance of other sources of safety information, such as scientific literature, for monitoring the safety profile and risk benefit balance of drugs.
“Scientific and medical literature” in general includes the published abstracts, or articles in medical or scientific journals, unpublished manuscripts involving case reports, and important safety findings or clinical studies including posters, letters to the editors, and associated communication from scientific conferences.
Over the past year, we have discussed the various challenges associated with monitoring scientific literature for adverse drug events (AE) on this blog. Between differences in regulations, monitoring literature in local languages, inspection readiness, and the rising sea of literature that must be monitored, there is no shortage of challenges in performing this task in an efficient manner. The number of literature articles that have to be handled continues to rise, and subsequently more AEs are identified. This facilitates the need to build a balanced search formula, which ensures all AEs are recognized and assessed, but doesn’t increase the unnecessary screening.
To share the best practices and help pharmacovigilance professionals to create a search formula that upkeeps the literature monitoring, Embase senior product development manager Dr. Ivan Krstic will discuss best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring. What’s more exciting, is that he will give a preview of Embase new search form – PV wizard. This new functionality will enable the users to more easily generate high-quality search string in support of identifying adverse drug events and improved to the ways to include Emtree terms, drug names and synonyms in a search query. Would you like to see it yourself? Join us on Wednesday March 22, 2017.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Sr. Marketing Manager, Life Sciences Audience at Elsevier
- The Dawn of a European Health Data Space – Opportunities
- Modulators, Biomarkers and Potential Treatments for COVID-19
- Rare disease research: grey literature is the new knowledge currency
- Exploring the effectiveness of traditional Chinese medicine against COVID-19
- Dedication to science drives a 20-year relationship between an information expert and a distinguished researcher